Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (7300)	1/22/2004 7:41:32 AM
From: Icebrg	Respond to of 10280

Quid There was an "In Play" message yesterday indicating that the share price was about to break through a previous high. As that succeeded, I guess there were more firebrands added by the technically inclined. Neurocrine is at least a year and a half away from an approval for Indiplon. There is really no reason for the stock to move. Apart from the fact that it is a very rock-solid company with a strong balance sheet. It's too early for Pfizer to make a move IMHO. Erik